 Novan, Inc. the Company or Novan NOVN today announced that the Company has conducted its Type C meeting with the U.S. Food and Drug Administration FDA regarding SB206 for the treatment of molluscum. The purpose of the meeting was to seek FDA feedback on the proposal to conduct one additional, well-controlled confirmatory study of SB206 to support a future New Drug Application NDA. 